On November 12, at the 93rd API China in Chongqing, we showcased a range of our bio-manufactured ingredients. This builds on our October showcase at CPHI Frankfurt 2025, underscoring our focused strategy for global market growth and commercial execution.

We highlighted our proprietary innovations and synthetic biology technology platform, which attracted considerable interest from attendees. Our platform allows us to respond rapidly to market needs, continuously improve production processes, and deliver products with superior purity, stability, sustainability, and cost-effectiveness. Supported by a fully integrated system spanning R&D, pilot-scale testing, large-scale production, and global supply, we provide high-quality, reliable raw materials for our customers worldwide.

From Frankfurt to Chongqing, our active presence at leading international events demonstrates our commitment to strengthening industry collaboration and expanding our global connections. Looking ahead, we will continue to drive innovation and foster industrial chain synergy, empowering the pharmaceutical industry with a competitive product portfolio and a dependable supply system for a greener, more efficient future.